Table of Contents
What changed
Investment income rose 23.3% to £43.6m from £35.3m, and the trust swung to a PBT of £11.5m from a £45.7m loss and to NPAT of £8.0m from a £48.8m loss. The result splits cleanly into a strong revenue return (£37.1m vs £33.8m) and a capital loss (–£29.1m vs –£81.4m prior), so the headline improvement is dominated by smaller capital-account losses rather than operational step-change. Operating cash flow improved sharply to £38.4m from £1.8m, cash balances nearly quadrupled to £14.3m, and total equity rose modestly to £435.6m. The total dividend was lifted to 23.80p from 23.40p (+1.7%), and the 31 August 2022 yield stood at 8.5% (2021: 7.8%).
What matters
- Income-side strength is genuine, capital-side is directional not fixed. Revenue return PBT of £41.1m is the cleaner read on the portfolio's cash-generative capacity and it underwrites the dividend raise. The £29.6m capital-account loss is smaller than prior year's £81.9m but still negative — the total-return story remains weak.
- Second-half shape is the central concern. HY22 NPAT was £29.7m against a full-year £8.0m, implying an H2 NPAT of roughly –£21.7m. Revenue was 92.6% front-loaded (£40.3m of £43.6m), meaning the second half saw both very light income recognition and materially worse capital marks.
- Dividend vs earnings cover has deteriorated. Payout against NPAT runs at roughly 455% this year; cover only works when viewed against revenue return, which is how closed-end income trusts typically frame it. Skeptical readers should track whether revenue return alone continues to cover distributions.
Expectations
No forward targets, NAV guidance or forecast portfolio yield were disclosed in the supplied excerpts, so the release cannot be benchmarked against management targets. Against the MSCI AC Asia Pacific ex Japan High Dividend Yield Index total return of 7.4% over one year, the filing provides no directly comparable trust total-return figure in the extracted data, limiting relative-performance judgement. The release does support the stated policy of a "growing total annual dividend per share" — the 1.7% raise is consistent — but does not support any claim about capital growth trajectory.
Quality of result
The revenue-return line is the durable component: 23.3% growth in investment income, £37.1m revenue profit, and £38.4m of operating cash flow are consistent and mutually reinforcing. PBT growth of 125.3% is the cleaner operating read versus NPAT growth of 116.3%, with the effective tax rate normalising to ~31.0% from 6.9% prior. However, the NPAT figure is heavily capital-markets-driven — it reflects smaller losses on the portfolio rather than earned returns — and the implied H2 NPAT loss of £21.7m shows how quickly the total result can flip on mark-to-market moves. The very strong OCF reflects investment-income receipts and portfolio turnover for a trust, not operating conversion in an industrial sense, and should not be read as free cash flow available for reinvestment or distribution beyond normal portfolio mechanics.
Unresolved
- What were the H2 capital losses attributable to (sector, geography, single names), and has portfolio positioning changed since year-end?
- Current gross borrowings and net debt at FY22 year-end were not provided, so gearing direction versus the £7.5m prior-year bank loan cannot be verified.
- With dividend of 23.80p and payout running at ~455% of NPAT, what is revenue-return cover per share and how much distributable reserve headroom exists?
- No capex, NTA per share, or share-price reference was provided, so discount/premium to NAV and total-return valuation cannot be assessed.
This briefing cannot assess portfolio composition, NAV total return, discount to NAV, or the sustainability of the dividend beyond what the revenue-return line and stated policy imply.
Key metrics
| Metric | FY22 | FY21 | Change |
|---|---|---|---|
| Revenue | $43.6m | $35.3m | +23.3% ↑ |
| Net profit after tax | $8.0m | −$48.8m | +116.3% ↑ |
| Net cash inflow from operating activities | $38.4m | $1.8m | +2058.5% ↑ |
| Operating profit | $11.9m | −$45.5m | +126.2% ↑ |
| Profit before tax | $11.5m | −$45.7m | +125.3% ↑ |
| Cash and cash equivalents | $14.3m | $3.9m | +268.9% ↑ |
| Total assets | $456.5m | $442.0m | +3.3% ↑ |
Reference: annolyse.ai/briefings/hfl-fy22
Analytical metrics
| Metric | FY22 | FY21 | Context |
|---|---|---|---|
| Effective tax rate | 31.0% | n/m (loss period) | prior loss period |
| Gross borrowings | — | $7.5m | — |
| Payout ratio vs NPAT | 455.1% | — | — |
| ROE (annualised) | 1.8% | -11.5% | Strengthening |
| HY22 share of FY22 revenue | 92.6% | — | Other half was 7.4% |
| HY22 share of FY22 NPAT | 373.1% | — | Other half was -273.1% |
| Profit from continuing operations | $8.0m | — | — |
Reference: annolyse.ai/briefings/hfl-fy22
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.